Experimental mRNA vaccine may protect against multiple Ebola viruses

Researchers have developed an experimental mRNA vaccine that may offer long-term protection against multiple deadly Ebola viruses, including the Bundibugyo strain currently causing outbreaks in the Democratic Republic of the Congo (DRC) and Uganda. The Bundibugyo virus has infected over 600 people in the DRC and led to two confirmed cases in Uganda, prompting the World Health Organization to declare the situation a public health emergency of international concern. The new vaccine demonstrated strong protective effects in animal trials against Bundibugyo, Zaire, and Sudan viruses, all members of the orthoebolavirus group responsible for severe human disease. The vaccine was created by combining mRNA sequences encoding the glycoproteins of each virus, as well as their shared nucleoprotein, encapsulated within a lipid nanoparticle to ensure delivery into cells. This approach addresses the challenge posed by the different glycoproteins that each virus uses to infect cells, while targeting the common nucleoprotein to stimulate broad immunity. In preclinical tests, mice and hamsters vaccinated with the formulation showed complete protection against exposure to all three viruses, marking a significant advance over existing vaccines, which currently only protect against the Zaire strain. While the results are promising, the vaccine has so far only been tested in rodents, and extensive further research is required to establish its safety and efficacy in humans. Experts emphasize the importance of trials in non-human primates, considered the gold standard for predicting human responses, before moving to clinical testing. Additionally, regulatory approval for a vaccine targeting multiple Ebola viruses may face challenges due to the complexity of demonstrating effectiveness against several pathogens simultaneously. This development is particularly important given the sporadic but deadly outbreaks of Ebola viruses beyond the well-known Zaire strain, for which no approved vaccines currently exist. A broad-spectrum vaccine could enhance outbreak preparedness and response, potentially reducing the global health threat posed by diverse Ebola viruses in affected regions.